---
title: "Jolly Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 510 million yuan, an increase of 21.00%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262928325.md"
description: "According to the Zhitong Finance APP, Jolly Pharmaceuticals released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.28 billion yuan, a year-on-year increase of 11.48%. The net profit attributable to shareholders of the listed company was 510 million yuan, a year-on-year increase of 21.00%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 509 million yuan, a year-on-year increase of 22.51%. The basic earnings per share were 0.7271 yuan"
datetime: "2025-10-27T14:40:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262928325.md)
  - [en](https://longbridge.com/en/news/262928325.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262928325.md)
---

# Jolly Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 510 million yuan, an increase of 21.00%

According to the Zhitong Finance APP, Jolly (300181.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.28 billion yuan, a year-on-year increase of 11.48%. The net profit attributable to shareholders of the listed company was 510 million yuan, a year-on-year increase of 21.00%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 509 million yuan, a year-on-year increase of 22.51%. The basic earnings per share were 0.7271 yuan

### Related Stocks

- [300181.CN](https://longbridge.com/en/quote/300181.CN.md)

## Related News & Research

- [Success of Uzbekistan's first London IPO will inspire others, fund chief says](https://longbridge.com/en/news/287033751.md)
- [ACEN Australia's NSW solar output surges 87% as new capacity powers up](https://longbridge.com/en/news/287096598.md)
- [Tata Power's (NSE:TATAPOWER) Problems Go Beyond Weak Profit](https://longbridge.com/en/news/286980045.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Uzbekistan raises $604m in landmark dual IPO debut](https://longbridge.com/en/news/286956985.md)